Who
Alan Sebulsky
Director
Company insider
Files Form 4 as: Director, MeiraGTx Holdings; Director, Parabilis Medicines; Director, Jazz Pharmaceuticals; Director, Arrow International.
In numbers
- Trades disclosed
- 86
- Buys
- 6
- Sells
- 2
- Bought
- $1.7M
- Sold
- $1.8M
- Companies
- 4
- Companies where not an officer
- 4
- First trade
- 18 Jan 2006
- Last trade
- 23 Sep 2026
- Last filed
- 24 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 23 Sep 2026filed 24 Sep 2026 | MGTX MeiraGTx Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 23 Sep 2026filed 24 Sep 2026 | MGTX MeiraGTx Holdingsoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 15 Jun 2026filed 16 Jun 2026 | PBLS Parabilis MedicinesBiotechnology | SEC FORM 4 Bought | $130K5,000 at $26.00 | filing |
| 15 Jun 2026filed 16 Jun 2026 | PBLS Parabilis MedicinesBiotechnology | SEC FORM 4 Bought | $110K4,065 at $27.10 | filing |
| 15 Jun 2026filed 16 Jun 2026 | PBLS Parabilis MedicinesBiotechnology | SEC FORM 4 Bought | $130K5,000 at $26.00 | filing |
| 15 Jun 2026filed 16 Jun 2026 | PBLS Parabilis MedicinesBiotechnology | SEC FORM 4 Bought | $110K4,065 at $27.10 | filing |
| 12 Jun 2026filed 16 Jun 2026 | PBLS Parabilis MedicinesBiotechnology | SEC FORM 4 Bought | $233K8,435 at $27.67 | filing |
| 12 Jun 2026filed 16 Jun 2026 | PBLS Parabilis MedicinesBiotechnology | SEC FORM 4 Bought | $233K8,435 at $27.67 | filing |
| 11 Jun 2026filed 15 Jun 2026 | PBLS Parabilis MedicinesBiotechnology | SEC FORM 4 Bought | $250K12,500 at $20.00 | filing |
| 11 Jun 2026filed 15 Jun 2026 | PBLS Parabilis MedicinesBiotechnology | SEC FORM 4 Bought | $250K12,500 at $20.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | PBLS Parabilis Medicinesoption or derivative · Biotechnology | SEC FORM 4 Code A | —39,792 at $0.00 | filing |
| 9 Jun 2026filed 11 Jun 2026 | PBLS Parabilis Medicinesoption or derivative · Biotechnology | SEC FORM 4 Code A | —39,792 at $0.00 | filing |
| 9 Mar 2012filed 13 Mar 2012 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $1.5M31,166 at $49.56 | filing |
| 18 Jan 2012filed 18 Jan 2012 | JAZZ Jazz Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code D | —16,079 | filing |
| 18 Jan 2012filed 18 Jan 2012 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Code D | —85,521 | filing |
| 18 Jan 2012filed 18 Jan 2012 | JAZZ Jazz Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —16,079 | filing |
| 18 Jan 2012filed 18 Jan 2012 | JAZZ Jazz PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —85,521 | filing |
| 11 Jan 2012filed 13 Jan 2012 | JAZZ Jazz Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 11 Jan 2012filed 13 Jan 2012 | JAZZ Jazz Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —10,000 at $0.00 | filing |
| 11 Jan 2012filed 13 Jan 2012 | JAZZ Jazz Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —12,500 at $0.00 | filing |
News
Parabilis Medicines (NASDAQ:PBLS) Shares Up 4.9% – Here's What HappenedPBLS · themarketsdaily.com · 19 Oct 2026Parabilis Medicines Initiates Dose-Ranging Clinical Study of Zolucatetide in Familial Adenomatous PolyposisPBLS · manilatimes.net · 14 Oct 2026
0 headlines in the last 90 days name Alan Sebulsky; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.